Profile | ADOPTERS

Logo	Name	Type	Year of Establishment	Industry Tag
	Kadimastem	Industry Player	2009	Medical
Hi we’re Kadimastem! Kadimastem Ltd. is a clinical-stage biotechnology company developing cell therapy solutions for ALS and diabetes, collaborating with TargetGene to expand its pipeline through next-generation gene-edited cell therapies aimed at delivering transformative, disease-modifying treatments worldwide.
	Viatris	Startup	2020	Medical
Hi we’re Viatris! Viatris Inc. (NASDAQ: VTRS), a global healthcare company bridging generics and branded medicines, has collaborated with a synthetic biology company to develop engineered bacteriophage therapies targeting ophthalmic bacterial infections.
	Bejo	Industry Player	1978	Agriculture
Hi we’re Bejo! Bejo, a privately held global vegetable breeding company, has partnered with Tropic to integrate its GEiGS® gene-editing platform with Bejo’s decades of carrot breeding expertise, aiming to develop next-generation non-GMO, disease-resilient crops better adapted to environmental stress and aligned with sustainable production standards.
	Weill Cornell Medicine	Industry Player	1898	Medical
Hi we’re Weill Cornell Medicine! Weill Cornell Medicine, a leading academic medical institution dedicated to patient care, research, and education, has entered a collaborative research agreement with Form Bio to apply gene editing technologies in developing drugs that reduce Alzheimer’s disease risk in patients with high-risk genetic variants.
	Tokyo Ohka Kogyo Co., Ltd.	Investor	1940	Material
Hi we’re Tokyo Ohka Kogyo Co., Ltd.! Tokyo Ohka Kogyo Co., Ltd. is a Japanese high-technology chemicals company specializing in photoresists, high-purity chemicals, and microfabrication materials and equipment. In synthetic biology, Tokyo Ohka Kogyo has invested in and partnered with bio-technology firms: for example, it joined as an investor in bitBiome, participating in a seed extension financing round.
	Paulig	Industry Player	1876	Food Synthetic Biology
Hi we’re Paulig! Paulig, an international food and beverage company focused on growing a sustainable food culture, through its venture arm PINC, invested in a synthetic biology company building a data-rich AI platform for next-generation enzyme discovery and design.
	NIIMBL	Others	2017	Medical
Hi we’re NIIMBL! The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership focused on advancing biopharmaceutical manufacturing, solving industry challenges, and developing the skilled workforce to meet industry’s needs.
	CLISEQ	Startup	2025	Medical
Hi we’re CLISEQ! CLISEQ is a biotech company developing hematology clinical decision-making diagnostics. Founded out of the Weizmann Institute, CLISEQ bridges world-class academic research and clinical practice to build transformative diagnostics and workflows.